Patents by Inventor Laurence R. Meyerson

Laurence R. Meyerson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for administering an NMDA receptor antagonist to a subject
    Patent number: 8598233
    Abstract: Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: December 3, 2013
    Assignee: Adamas Pharmacueticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Composition and Method for Treating Neurological Disease
    Publication number: 20130317115
    Abstract: A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day.
    Type: Application
    Filed: August 2, 2013
    Publication date: November 28, 2013
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Compositions for the treatment of CNS-related conditions
    Patent number: 8580858
    Abstract: The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: November 12, 2013
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Method and composition for administering an NMDA receptor antagonist to a subject
    Patent number: 8426472
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: April 23, 2013
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Composition and method for treating neurological disease
    Patent number: 8389578
    Abstract: The invention provides methods and compositions for treating or preventing neurological disorders.
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: March 5, 2013
    Assignee: Adamas Pharmaceuticals, Inc
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Method for administering an NMDA receptor antagonist to a subject
    Patent number: 8362085
    Abstract: The invention provides methods for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: January 29, 2013
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Compositions for the treatment of CNS-related conditions
    Patent number: 8338485
    Abstract: The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: December 25, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Methods for the treatment of CNS-related conditions
    Patent number: 8338486
    Abstract: The invention provides methods for administering extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form of memantine achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: December 25, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Composition for administering an NMDA receptor antagonist to a subject
    Patent number: 8329752
    Abstract: The invention provides compostions for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: December 11, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Methods for the Treatment of CNS-Related Conditions
    Publication number: 20120288560
    Abstract: The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine.
    Type: Application
    Filed: July 26, 2012
    Publication date: November 15, 2012
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Thimothy J. Fultz, Laurence R. Meyerson
  • Methods and compositions for the treatment of CNS-related conditions
    Patent number: 8293794
    Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: October 23, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT
    Publication number: 20120264978
    Abstract: The invention provides compostions for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Application
    Filed: June 28, 2012
    Publication date: October 18, 2012
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • METHODS FOR THE TREATMENT OF CNS-RELATED CONDITIONS
    Publication number: 20120264783
    Abstract: The invention provides methods for administering extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form of memantine achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Application
    Filed: June 28, 2012
    Publication date: October 18, 2012
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • COMPOSITIONS FOR THE TREATMENT OF CNS-RELATED CONDITIONS
    Publication number: 20120264782
    Abstract: The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Application
    Filed: June 28, 2012
    Publication date: October 18, 2012
    Applicant: ADAMAS PHARMACEUTICALS, INC.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • METHOD FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT
    Publication number: 20120264829
    Abstract: The invention provides methods for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Application
    Filed: June 28, 2012
    Publication date: October 18, 2012
    Applicant: Adamas Pharmaceuticals, Inc. a Delaware Corporation
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Methods and compositions for the treatment of CNS-related conditions
    Patent number: 8283379
    Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: October 9, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Method and composition for administering an NMDA receptor antagonist to a subject
    Patent number: 8173708
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: May 8, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Method and composition for administering an NMDA receptor antagonist to a subject
    Patent number: 8168209
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: May 1, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT
    Publication number: 20120058182
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Application
    Filed: April 9, 2010
    Publication date: March 8, 2012
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT
    Publication number: 20120045508
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Application
    Filed: April 9, 2010
    Publication date: February 23, 2012
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth